EGFR and cancer: Moreover, drug sensitivity, genetic, and histologic profiling of the SCLC-transformed EGFR mutants further suggests that chronic EGFR inhibition can lead to the development of cancers that adopt a classical SCLC genotype and phenotype than other TKI-resistant cell states [59].